Background: To investigate the safety, efficacy, and follow-up outcomes of microwave ablation (MWA) in patients with breast fibroadenoma.
Methods: An institutional review board-approved this study of patients treated with MWA for breast fibroadenoma from October 2017 to March 2019. Clinical features of patients and breast fibroadenoma were analyzed. At follow-up all patients received physical examination and ultrasound imaging.
Results: In total, 171 patients with 271 lesions were enrolled. The mean lesion diameter was 1.35 ± 0.47 cm. The results revealed differential lesion states, including stability, enlargement, reduction, and complete regression, at 1-6, 6-12, and >12 months of follow-up. The size was reduced in 22.14% (31/140), 26.36% (29/110), and 36.36% (16/44) of the lesions at 1-6, 6-12, and >12 months of follow-up, respectively. The proportion of lesions with complete regression was 24.29% (34/140) at 1-6 months, 45.45% (50/110) at 6-12 months, and 40.91% (18/44) at >12 months of follow up. There was no significant relationship between the curative effect and age, lesion location, and blood flow in patients with breast fibroadenoma after MWA ( > .05), but there was statistically significant relationship with lesion diameter (categorized as <1.5 cm and ≥1.5 cm) ( < .05).
Conclusions: The current evidence indicates that MWA is a safe and effective method for treating breast fibroadenoma. Nevertheless, further large-scale prospective trials and well-designed future studies are warranted to validate our findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02656736.2021.1895329 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Investigation of Somatostatin Receptors as a Potential Target in Breast Phyllodes Tumours.
Diagnostics (Basel)
December 2024
Department of Surgery, School of Medicine, Acıbadem Mehmet Ali Aydınlar University, 34752 Istanbul, Turkey.
Background: Somatostatin receptors (SSTRs) are expressed in most neuroendocrine neoplasms, particularly in gastroenteropancreatic neuroendocrine tumours, and have been utilised as diagnostic markers and therapeutic targets. The radioiodinated somatostatin analogue 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid- Tyr3-octreotate (DOTATATE) has been employed for SSTR targeting for either diagnostic or therapeutic purposes depending on the labelling with Gallium or Lutetium, respectively. SSTR expression is reported in a subset of breast adenocarcinoma and breast neuroendocrine carcinomas; however, minimal knowledge exists regarding their expression in fibroepithelial (biphasic) breast lesions such as fibroadenoma and phyllodes tumours.
View Article and Find Full Text PDFGrating-based x-ray dark-field mammography: Assessing complementary imaging information in simple cystic lesions and typical fibroadenoma.
Med Phys
January 2025
Breast Imaging Department, Red Cross Hospital Munich, Munich, Germany.
Background: A significant proportion of false positive recalls of mammography-screened women is due to benign breast cysts and simple fibroadenomas. These lesions appear mammographically as smooth-shaped dense masses and require the recalling of women for a breast ultrasound to obtain complementary imaging information. They can be identified safely by ultrasound with no need for further assessment or treatment.
View Article and Find Full Text PDFRole of centchroman in regression of fibroadenoma: A 2-arm randomized control trial.
Clinics (Sao Paulo)
December 2024
Department of General Surgery, Dr. RMLIMS, Lucknow, Uttar Pradesh, India.
Background: Fibroadenomas are common benign breast lumps that can cause anxiety due to malignancy concerns, and Centchroman, a selective estrogen receptor modulator, has shown promise in reducing their size. This study aimed to evaluate the efficacy of Centchroman in reducing fibroadenoma size, mastalgia, anxiety, and depression in affected patients.
Methodology: A parallel-arm randomized controlled trial was conducted at a tertiary care Breast Clinic with 104 patients aged 18‒45 years having fibroadenomas ≤ 3 cm.
Proliferative Myositis of the Breast in a Patient with Contralateral Phyllodes Tumor: A Unique Pseudomalignant Lesion.
Ann Ital Chir
December 2024
Department of Pathology, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, 34147 İstanbul, Türkiye.
Article Synopsis
- A case of proliferative myositis (PM) of the breast is presented, marking only the second documented instance in English literature.
- A 49-year-old woman developed a rapidly growing mass in her right breast after surgeries for other tumors, leading to initial concerns about malignancy; extensive immunohistochemical testing ultimately diagnosed PM.
- The findings highlight the critical need to identify pseudomalignant conditions in order to prevent unnecessary aggressive treatments.
OSTEOPONTIN-REGULATED CHANGES IN THE MAST CELL POPULATION ASSOCIATED WITH BREAST CANCER.
Exp Oncol
December 2024
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine.
Article Synopsis
- The study examines how mast cells (MCs) in the tumor microenvironment (TME) relate to breast cancer (BCa) characteristics, focusing on their infiltration density and functional activity alongside osteopontin (OP) expression.
- Research involved analyzing tissue samples from 93 patients to assess MC presence and OP levels, finding correlations between MC characteristics and various malignancy indicators like tumor size and lymph node involvement.
- Results suggest that OP expression is linked to MC activity and BCa aggressiveness, indicating potential for using these factors in predicting tumor severity and guiding treatment strategies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!